Division of Allergy and Immunology, University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Division of Pathology, University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Gastroenterology. 2022 May;162(6):1635-1649. doi: 10.1053/j.gastro.2022.01.022. Epub 2022 Jan 25.
BACKGROUND & AIMS: Colonic eosinophilia, an enigmatic finding often referred to as eosinophilic colitis (EoC), is a poorly understood condition. Whether EoC is a distinct disease or a colonic manifestation of eosinophilic gastrointestinal diseases (EGIDs) or inflammatory bowel disease (IBD) is undetermined.
Subjects with EoC (n = 27) and controls (normal [NL, n = 20], Crohn's disease [CD, n = 14]) were enrolled across sites associated with the Consortium of Eosinophilic Gastrointestinal Disease Researchers. EoC was diagnosed as colonic eosinophilia (ascending ≥100, descending ≥85, sigmoid ≥65 eosinophils/high-power field) with related symptoms. Colon biopsies were subjected to RNA sequencing. Associations between gene expression and histologic features were analyzed with Spearman correlation; operational pathways and cellular constituents were computationally derived.
We identified 987 differentially expressed genes (EoC transcriptome) between EoC and NL (>1.5-fold change, P < .05). Colonic eosinophil count correlated with 31% of EoC transcriptome, most notably with CCL11 and CLC (r = 0.78 and 0.77, P < .0001). Among EoC and other EGIDs, there was minimal transcriptomic overlap and minimal evidence of a strong allergic type 2 immune response in EoC compared with other EGIDs. Decreased cell cycle and increased apoptosis in EoC compared with NL were identified by functional enrichment analysis and immunostaining using Ki-67 and cleaved caspase-3. Pericryptal circumferential eosinophil collars were associated with the EoC transcriptome (P < .001). EoC transcriptome-based scores were reversible with disease remission and differentiated EoC from IBD, even after controlling for colonic eosinophil levels (P < .0001).
We established EoC transcriptomic profiles, identified mechanistic pathways, and integrated findings with parallel IBD and EGID data. These findings establish EoC as a distinct disease compared with other EGIDs and IBD, thereby providing a basis for improving diagnosis and treatment.
结肠嗜酸性粒细胞增多症,一种常被称为嗜酸性结肠炎(EoC)的神秘表现,是一种尚未被充分了解的病症。EoC 是否是一种独特的疾病,还是嗜酸性胃肠道疾病(EGIDs)或炎症性肠病(IBD)的结肠表现尚不确定。
在与嗜酸性胃肠道疾病研究人员联盟相关的多个研究中心招募了 EoC 患者(n=27)和对照组(正常[NL,n=20]、克罗恩病[CD,n=14])。EoC 被诊断为结肠嗜酸性粒细胞增多症(升结肠嗜酸性粒细胞计数≥100,降结肠嗜酸性粒细胞计数≥85,乙状结肠嗜酸性粒细胞计数≥65/高倍视野)伴相关症状。对结肠活检组织进行 RNA 测序。使用 Spearman 相关性分析来分析基因表达与组织学特征之间的关联;通过计算方法获得操作途径和细胞成分。
我们在 EoC 与 NL 之间鉴定出 987 个差异表达基因(EoC 转录组)(差异倍数>1.5 倍,P<.05)。结肠嗜酸性粒细胞计数与 31%的 EoC 转录组相关,与 CCL11 和 CLC 的相关性最强(r=0.78 和 0.77,P<.0001)。在 EoC 与其他 EGIDs 之间,EoC 与其他 EGIDs 的转录组重叠很少,与其他 EGIDs 相比,EoC 中几乎没有强烈的 2 型过敏样免疫反应的证据。与 NL 相比,EoC 中细胞周期减少和细胞凋亡增加,通过 Ki-67 和 cleaved caspase-3 免疫染色进行功能富集分析可证实这一点。EoC 转录组相关评分可随疾病缓解而逆转,并可区分 EoC 与 IBD,即使在控制结肠嗜酸性粒细胞水平后也是如此(P<.0001)。
我们建立了 EoC 转录组谱,确定了机制途径,并将这些发现与平行的 IBD 和 EGID 数据进行了整合。这些发现将 EoC 确立为一种与其他 EGIDs 和 IBD 不同的独特疾病,从而为改善诊断和治疗提供了基础。